[Metrorrhagia and tamoxifen. Apropos of 22 patients treated for cancer of the breast].
The authors report 22 cases of metrorrhagia occurring in the course of adjuvant hormonal therapy for breast cancer using tamoxifen. The anti-oestrogenic effect of this drug is associated with a variable agonistic effect that has been observed in organs with steroid receptors, and especially in the uterus. In this series, the cause of the abnormal bleeding is explained in 17 out of the 22 cases (ie, 3 out of 4) as a paradoxical oestrogen-like effect on the mucosa of the uterus. Two cancers of the endometrium were diagnosed.
Le Bouëdec
G
G
Centre Jean Perrin, Service de Chirurgie, Clermont-Ferrand.
De Latour
M
M
Feillel
V
V
Dauplat
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D002277:Carcinoma / Q000737:chemistry / Q000188:drug therapy*; D004717:Endometrium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D008796:Metrorrhagia / Q000139:chemically induced*; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D013629:Tamoxifen / Q000009:adverse effects*; D013997:Time Factors; D014599:Uterus / Q000187:drug effects / Q000473:pathology
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen
Métrorragies et tamoxifène. A propos de 22 patientes traitées pour cancer du sein.